{
    "id": 29016,
    "fullName": "PPL - NTRK1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PPL-NTRK1 results from the fusion of PPL and NTRK1 (PMID: 25384085, PMID: 29466156). PPL-NTRK1 has been associated with thyroid carcinoma (PMID: 25384085), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                },
                {
                    "id": 5909,
                    "pubMedId": 25384085,
                    "title": "Anchored multiplex PCR for targeted next-generation sequencing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25384085"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5493,
        "geneSymbol": "PPL",
        "terms": [
            "PPL"
        ]
    },
    "variant": "PPL - NTRK1",
    "createDate": "11/27/2018",
    "updateDate": "10/03/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15296,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a patient with advanced solid tumor harboring a PPL-NTRK1 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30943,
                "profileName": "PPL - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30943,
            "profileName": "PPL - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19340,
                    "name": "Larotrectinib",
                    "profileName": "PPL - NTRK1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}